Clinical Trials Logo
  1. Home
  2. Hepatitis B Infection
  3. NCT01488526

Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus

Hepatitis B Infection Clinical Trial

Official title:
Tenofovir Disoproxil Fumarate in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus in Highly Viremic Mothers

Clinical Trial Summary

Immunoprophylaxis failure of hepatitis B virus (HBV) leading to vertical transmission remains a concern and has been reported in approximately 8-15% of infants born to hepatitis B e antigen (HBeAg) positive mothers with high levels of HBV DNA. Maternal HBV DNA > 6log10 copies/mL (or >200,000 IU/mL) is the major risk for the mother-to-child transmission. Prior observational studies have shown that antiviral therapy including lamivudine or telbivudine use during late pregnancy can safely reduce the rate of vertical transmission in this special population compared to untreated patients.

Tenofovir Disoproxil (TDF), a pregnancy category B medication, reduces HBV DNA and normalizes serum alanine aminotransferase (ALT) in chronic hepatitis B patients (CHB) with few adverse effects. Two aspects on tenofovir use in pregnancy will be evaluated prospectively in this study:

1. The data on its tolerability and safety in HBeAg+ pregnant women with HBV DNA > 6log10 copies/mL (or > 200,000 IU/mL) during late pregnancy and infants.

2. Its efficacy in the reduction of HBV vertical transmission rate.

Clinical Trial Description

Eligible mothers will be randomized (1:1) to either TDF-treated group or untreated group with about 100 subjects in each arm. The treatment group will receive TDF starting at week 30-32 of gestation until week 4 postpartum; follow up will continue until post-partum week 28 and infants age of 28 weeks. Untreated group will receive the standard of care with similar follow-up schedule as the treatment group. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01488526
Study type Interventional
Source New Discovery LLC
Contact
Status Completed
Phase Phase 4
Start date March 1, 2012
Completion date June 28, 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04704024 - Reducing Vertical Transmission of Hepatitis B in Africa Phase 3
Active, not recruiting NCT02143401 - Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT00371150 - Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Phase 4
Active, not recruiting NCT03519113 - HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 Phase 2/Phase 3
Completed NCT01788371 - Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus Phase 4
Recruiting NCT06368479 - A Prospective Cross-Sectional Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings N/A
Terminated NCT02826018 - A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection Phase 1
Completed NCT01970254 - Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy
Completed NCT00489099 - A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054) Phase 3
Recruiting NCT03476083 - Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission Phase 4
Recruiting NCT03865966 - Hepatitis B Virus Infection After Liver Transplantation in Children
Completed NCT03627507 - Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh. Phase 2/Phase 3
Completed NCT02443233 - Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong N/A
Completed NCT00841477 - An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users Phase 3
Terminated NCT03887702 - Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors Phase 3
Completed NCT02304315 - A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients Phase 2
Active, not recruiting NCT05117541 - Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection
Not yet recruiting NCT06368466 - A Prospective Cross-Sectional Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites N/A